全文获取类型
收费全文 | 319篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 2篇 |
妇产科学 | 6篇 |
基础医学 | 71篇 |
口腔科学 | 7篇 |
临床医学 | 45篇 |
内科学 | 52篇 |
皮肤病学 | 3篇 |
神经病学 | 14篇 |
特种医学 | 4篇 |
外科学 | 30篇 |
综合类 | 13篇 |
预防医学 | 33篇 |
眼科学 | 11篇 |
药学 | 23篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2021年 | 4篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 7篇 |
2014年 | 5篇 |
2013年 | 9篇 |
2012年 | 11篇 |
2011年 | 17篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 21篇 |
2007年 | 20篇 |
2006年 | 17篇 |
2005年 | 11篇 |
2004年 | 9篇 |
2003年 | 13篇 |
2002年 | 9篇 |
2001年 | 3篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 3篇 |
1988年 | 6篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1979年 | 3篇 |
1978年 | 7篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1974年 | 7篇 |
1973年 | 4篇 |
1972年 | 6篇 |
1971年 | 3篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1967年 | 2篇 |
1966年 | 5篇 |
1965年 | 3篇 |
1962年 | 2篇 |
1954年 | 3篇 |
1944年 | 2篇 |
1940年 | 2篇 |
1939年 | 2篇 |
1934年 | 2篇 |
1931年 | 3篇 |
排序方式: 共有340条查询结果,搜索用时 0 毫秒
1.
Scalp electrical recording during paralysis: quantitative evidence that EEG frequencies above 20 Hz are contaminated by EMG. 总被引:2,自引:0,他引:2
Emma M Whitham Kenneth J Pope Sean P Fitzgibbon Trent Lewis C Richard Clark Stephen Loveless Marita Broberg Angus Wallace Dylan DeLosAngeles Peter Lillie Andrew Hardy Rik Fronsko Alyson Pulbrook John O Willoughby 《Clinical neurophysiology》2007,118(8):1877-1888
OBJECTIVE: To identify the possible contribution of electromyogram (EMG) to scalp electroencephalogram (EEG) rhythms at rest and induced or evoked by cognitive tasks. METHODS: Scalp EEG recordings were made on two subjects in presence and absence of complete neuromuscular blockade, sparing the dominant arm. The subjects undertook cognitive tasks in both states to allow direct comparison of electrical recordings. RESULTS: EEG rhythms in the paralysed state differed significantly compared with the unparalysed state, with 10- to 200-fold differences in the power of frequencies above 20 Hz during paralysis. CONCLUSIONS: Most of the scalp EEG recording above 20 Hz is of EMG origin. Previous studies measuring gamma EEG need to be re-evaluated. SIGNIFICANCE: This has a significant impact on measurements of gamma rhythms from the scalp EEG in unparalysed humans. It is to be hoped that signal separation methods will be able to rectify this situation. 相似文献
2.
J-H. Longeville P. De La M. Hall P. Dolan A. W. Holt P. E. Lillie J. A. R. Williams R. T. A. Padbury 《HPB surgery》1997,10(3):159-162
We describe a case of giant cavernous haemangioma of the liver with disseminated intravascular coagulopathy (Kasabach-Merritt syndrome) which was cured by orthotopic liver transplant.A 47 year old man presented with bleeding and tender massive hepatomegaly after tooth extraction. Investigations showed disseminated intravascular coagulopathy and a giant hepatic haemangioma involving both lobes of the liver. Initial treatment failed to resolve the coagulopathy and liver resection was attempted. At laparotomy the turnout was unresectable and the only option for cure was to offer a liver transplantation. The orthotopic liver transplant was performed 20 days after initial laparotomy. Subsequently, all coagulation parameters returned to normal and the patient remains well after 12 months. Orthotopic liver transplant can be considered for giant hepatic haemangioma with Kasabach-Merritt syndrome when resection is necessary and a partial hepatectomy is not technically feasible. 相似文献
3.
Thomas Patrick S. Jr; Fraley Gregory S.; Damian Vincent; Woodke Lillie B.; Zapata Francisco; Sopher Bryce L.; Plymate Stephen R.; La Spada Albert R. 《Human molecular genetics》2006,15(19):2972
Human Molecular 相似文献
4.
5.
6.
7.
8.
9.
10.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age 总被引:8,自引:2,他引:8
Mileshkin L Biagi JJ Mitchell P Underhill C Grigg A Bell R McKendrick J Briggs P Seymour JF Lillie K Smith JG Zeldis JB Prince HM 《Blood》2003,102(1):69-77
Relapsed or refractory multiple myeloma has a poor outlook. Some patients respond to thalidomide; however, criteria for predicting response have not been conclusively identified. We initiated a prospective multicenter phase 2 trial in patients with relapsed/refractory myeloma using thalidomide up to the maximum dose, 800 mg/d. Interferon-alpha-2B (1.5-3.0 x 10(6) U, subcutaneously, 3 times per week) was added at week 12 if disease was responsive or stable. Patients intolerant of interferon continued thalidomide alone. Thalidomide with or without interferon was continued until disease progression. Objectives were to determine toxicity, response rate (RR), progression-free survival (PFS), and overall survival (OS) and to elucidate relevant prognostic factors. We enrolled 75 patients, with median age 64 years (range, 36-83 years). Median individual maximum-tolerated dose of thalidomide was 600 mg/d; 41% reached 800 mg/d. Overall RR was 28%, and 55% stable disease (SD). The only predictor for response was age 65 years or younger (38% versus 17%; P =.043). At 18 months median follow-up, the actuarial median PFS and OS were 5.5 and 14.6 months, respectively. Multivariate analysis for OS demonstrated age exceeding 65 years (median, 9.2 months versus longer than 26 months; P =.011), raised serum lactate dehydrogenase (P =.002), and raised serum creatinine (P =.007) predicted inferior outcomes. Nineteen patients received interferon. Ten discontinued owing to toxicity. Four of 12 patients who received interferon for longer than 4 weeks were converted from SD to partial response. Our findings confirm substantial activity of thalidomide in relapsed/refractory myeloma. Interferon may improve response in selected patients, but is often not tolerated. The inferior outcome demonstrated in those with the identified prognostic factors is important in planning management for such patients. 相似文献